HK1198125A1 - Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy - Google Patents
Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapyInfo
- Publication number
- HK1198125A1 HK1198125A1 HK14111635.2A HK14111635A HK1198125A1 HK 1198125 A1 HK1198125 A1 HK 1198125A1 HK 14111635 A HK14111635 A HK 14111635A HK 1198125 A1 HK1198125 A1 HK 1198125A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- predicting
- efficacy
- methods
- cardiovascular diseases
- treating cardiovascular
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161508923P | 2011-07-18 | 2011-07-18 | |
US201161509359P | 2011-07-19 | 2011-07-19 | |
PCT/US2012/047238 WO2013012945A1 (en) | 2011-07-18 | 2012-07-18 | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1198125A1 true HK1198125A1 (en) | 2015-03-13 |
Family
ID=47558450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14111635.2A HK1198125A1 (en) | 2011-07-18 | 2014-11-18 | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
Country Status (13)
Country | Link |
---|---|
US (5) | US8748110B2 (xx) |
EP (2) | EP3173093B1 (xx) |
JP (2) | JP6134316B2 (xx) |
CN (2) | CN103796669B (xx) |
AU (2) | AU2012284039B2 (xx) |
BR (1) | BR112014001283A2 (xx) |
CA (1) | CA2842072A1 (xx) |
DK (1) | DK2734222T3 (xx) |
ES (1) | ES2611403T3 (xx) |
HK (1) | HK1198125A1 (xx) |
MX (1) | MX351428B (xx) |
PL (1) | PL2734222T3 (xx) |
WO (1) | WO2013012945A1 (xx) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
SI3072978T1 (sl) | 2002-05-09 | 2018-11-30 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 kot marker za kardiovaskularne bolezni |
ATE476657T1 (de) | 2006-04-24 | 2010-08-15 | Critical Care Diagnostics Inc | Vorhersage von letalität und detektion von schweren erkrankungen |
WO2007143295A2 (en) * | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
PT2021796E (pt) | 2006-05-01 | 2012-04-19 | Critical Care Diagnostics Inc | Diagnóstico de doença cardiovascular |
ES2542343T3 (es) * | 2006-05-02 | 2015-08-04 | Critical Care Diagnostics, Inc. | Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular |
PT2269063E (pt) | 2008-04-18 | 2013-11-27 | Critical Care Diagnostics Inc | Predição do risco de eventos cardíacos adversos maiores |
RS54762B1 (sr) | 2010-04-09 | 2016-10-31 | Critical Care Diagnostics Inc | Solubilna humana st-2 antitela i eseji |
EP2686689B1 (en) | 2011-03-17 | 2019-08-07 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
BR112014001283A2 (pt) | 2011-07-18 | 2017-02-21 | Critical Care Diagnostics Inc | métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício |
CN104507383B (zh) | 2012-05-18 | 2018-08-28 | 重症监护诊断股份有限公司 | 用于治疗或预报室性快速性心律失常事件风险的方法 |
DK2885641T3 (da) | 2012-08-16 | 2018-01-29 | Critical Care Diagnostics Inc | Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension |
WO2014031764A1 (en) | 2012-08-21 | 2014-02-27 | Critical Care Diagnostics, Inc. | Multimarker risk stratification |
CN104017056B (zh) * | 2014-06-27 | 2016-08-17 | 国科戎安生物科技(北京)有限公司 | St2蛋白抑制剂多肽及其应用 |
CN104017057B (zh) * | 2014-06-27 | 2016-08-24 | 榆林市第一医院 | 一种st2蛋白抑制剂多肽及其应用 |
AU2014407088B2 (en) | 2014-09-26 | 2021-09-23 | Somalogic Operating Co., Inc. | Cardiovascular risk event prediction and uses thereof |
EP3218403B1 (en) | 2014-11-10 | 2020-05-13 | F.Hoffmann-La Roche Ag | Anti-interleukin-33 antibodies and uses thereof |
US20160168640A1 (en) | 2014-11-10 | 2016-06-16 | Genentech, Inc. | Therapeutic and diagnostic methods for il-33-mediated disorders |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
CN105259353B (zh) * | 2015-10-15 | 2017-03-22 | 北京市心肺血管疾病研究所 | 一种主动脉瘤和/或主动脉夹层患者血液中可溶性st2的检测试剂盒及检测方法 |
US20190110700A1 (en) * | 2016-04-15 | 2019-04-18 | Omron Corporation | Biological information analysis device, system, and program |
JP6983223B2 (ja) * | 2016-04-18 | 2021-12-17 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 一般集団におけるlvhへの進行因子の同定のための可溶性st2 |
CN108982871B (zh) * | 2018-07-19 | 2021-09-24 | 北京市心肺血管疾病研究所 | 血清sST2在小儿扩张型心肌病预后中的应用 |
CN115605507A (zh) | 2020-03-13 | 2023-01-13 | 基因泰克公司(Us) | 抗白介素-33抗体及其用途 |
RU2741195C1 (ru) * | 2020-03-27 | 2021-01-22 | Государственное бюджетное учреждение здравоохранения Нижегородской области "Нижегородская областная клиническая больница им. Н.А. Семашко" | Способ прогнозирования ургентных сердечно-сосудистых осложнений при остром коронарном синдроме у больных с онкологическим заболеванием в анамнезе |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4302386A (en) | 1978-08-25 | 1981-11-24 | The Ohio State University | Antigenic modification of polypeptides |
US4105776A (en) | 1976-06-21 | 1978-08-08 | E. R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
JPS533020A (en) | 1976-06-29 | 1978-01-12 | Matsushita Electric Ind Co Ltd | Static picture reception unit |
US4316906A (en) | 1978-08-11 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of substituted prolines |
IL58849A (en) | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
US4508729A (en) | 1979-12-07 | 1985-04-02 | Adir | Substituted iminodiacids, their preparation and pharmaceutical compositions containing them |
US4344949A (en) | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
ZA817261B (en) | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
US4337201A (en) | 1980-12-04 | 1982-06-29 | E. R. Squibb & Sons, Inc. | Phosphinylalkanoyl substituted prolines |
US4410520A (en) | 1981-11-09 | 1983-10-18 | Ciba-Geigy Corporation | 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids |
GB2128984B (en) | 1982-05-12 | 1985-05-22 | Hoffmann La Roche | Diaza-bicyclic compounds |
JPS5911218U (ja) | 1982-07-14 | 1984-01-24 | 松下電器産業株式会社 | 燃焼器 |
US4816463A (en) | 1986-04-01 | 1989-03-28 | Warner-Lambert Company | Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity |
CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
US4772684A (en) | 1987-01-20 | 1988-09-20 | Triton Biosciences, Inc. | Peptides affecting blood pressure regulation |
US5081127A (en) | 1988-01-07 | 1992-01-14 | E. I. Du Pont De Nemours And Company | Substituted 1,2,3-triazole angiotensin II antagonists |
US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
US5073566A (en) | 1989-11-30 | 1991-12-17 | Eli Lilly And Company | Angiotensin ii antagonist 1,3-imidazoles and use thereas |
US5085992A (en) | 1990-07-19 | 1992-02-04 | Merck & Co., Inc. | Microbial transformation process for antihypertensive products |
US5087634A (en) | 1990-10-31 | 1992-02-11 | G. D. Searle & Co. | N-substituted imidazol-2-one compounds for treatment of circulatory disorders |
AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
GB2372114A (en) * | 2001-02-07 | 2002-08-14 | Cardionetics Ltd | A computerised physical exercise program for rehabilitating cardiac health patients together with remote monitoring |
SI3072978T1 (sl) * | 2002-05-09 | 2018-11-30 | The Brigham And Women's Hospital, Inc. | 1L1RL-1 kot marker za kardiovaskularne bolezni |
ATE476657T1 (de) * | 2006-04-24 | 2010-08-15 | Critical Care Diagnostics Inc | Vorhersage von letalität und detektion von schweren erkrankungen |
WO2007143295A2 (en) | 2006-04-27 | 2007-12-13 | Critical Care Diagnostics, Inc. | Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease |
PT2021796E (pt) | 2006-05-01 | 2012-04-19 | Critical Care Diagnostics Inc | Diagnóstico de doença cardiovascular |
ES2542343T3 (es) | 2006-05-02 | 2015-08-04 | Critical Care Diagnostics, Inc. | Diagnóstico diferencial entre enfermedad pulmonar y cardiovascular |
RU2355295C1 (ru) * | 2007-10-23 | 2009-05-20 | Федеральное Государственное Учреждение "Саратовский Научно-Исследовательский Институт Кардиологии Росмедтехнологий" | Способ реабилитации больных ибс |
PT2269063E (pt) | 2008-04-18 | 2013-11-27 | Critical Care Diagnostics Inc | Predição do risco de eventos cardíacos adversos maiores |
GB0818650D0 (en) * | 2008-10-10 | 2008-11-19 | Uni I Oslo | Methods |
JP5584695B2 (ja) * | 2008-11-11 | 2014-09-03 | ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Adm及びbnpのレベルを決定することによる心疾患に罹患した患者の予後診断及びリスク評価 |
RS54762B1 (sr) | 2010-04-09 | 2016-10-31 | Critical Care Diagnostics Inc | Solubilna humana st-2 antitela i eseji |
EP2686689B1 (en) | 2011-03-17 | 2019-08-07 | Critical Care Diagnostics, Inc. | Methods predicting risk of an adverse clinical outcome |
BR112014001283A2 (pt) | 2011-07-18 | 2017-02-21 | Critical Care Diagnostics Inc | métodos de tratamento de doenças cardiovasculares e prevenção da eficácia da terapia de exercício |
KR20140108675A (ko) | 2012-01-04 | 2014-09-12 | 웰즐리 파마슈티컬스 엘엘씨 | 배뇨 빈도를 감소시키기 위한 연장-방출형 제제 및 이의 사용 방법 |
CN104507383B (zh) | 2012-05-18 | 2018-08-28 | 重症监护诊断股份有限公司 | 用于治疗或预报室性快速性心律失常事件风险的方法 |
DK2885641T3 (da) | 2012-08-16 | 2018-01-29 | Critical Care Diagnostics Inc | Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension |
WO2014031764A1 (en) | 2012-08-21 | 2014-02-27 | Critical Care Diagnostics, Inc. | Multimarker risk stratification |
JP6655016B2 (ja) | 2014-01-10 | 2020-02-26 | クリティカル ケア ダイアグノスティクス インコーポレイテッド | 心不全のリスクを決定するための方法 |
USD770057S1 (en) | 2014-04-14 | 2016-10-25 | Critical Care Diagnostics, Inc. | Blood test kit |
US10079073B2 (en) | 2014-12-11 | 2018-09-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
US10324089B2 (en) | 2014-12-11 | 2019-06-18 | Critical Care Diagnostics, Inc. | Test apparatus and methods for ST2 cardiac biomarker |
-
2012
- 2012-07-18 BR BR112014001283A patent/BR112014001283A2/pt not_active Application Discontinuation
- 2012-07-18 WO PCT/US2012/047238 patent/WO2013012945A1/en active Application Filing
- 2012-07-18 CN CN201280045405.6A patent/CN103796669B/zh not_active Expired - Fee Related
- 2012-07-18 EP EP16192678.7A patent/EP3173093B1/en not_active Not-in-force
- 2012-07-18 US US13/552,533 patent/US8748110B2/en not_active Expired - Fee Related
- 2012-07-18 MX MX2014000715A patent/MX351428B/es active IP Right Grant
- 2012-07-18 JP JP2014521739A patent/JP6134316B2/ja not_active Expired - Fee Related
- 2012-07-18 CA CA2842072A patent/CA2842072A1/en not_active Abandoned
- 2012-07-18 DK DK12814331.0T patent/DK2734222T3/en active
- 2012-07-18 PL PL12814331T patent/PL2734222T3/pl unknown
- 2012-07-18 EP EP12814331.0A patent/EP2734222B1/en not_active Not-in-force
- 2012-07-18 CN CN201610902184.XA patent/CN106908604B/zh active Active
- 2012-07-18 AU AU2012284039A patent/AU2012284039B2/en not_active Ceased
- 2012-07-18 ES ES12814331.0T patent/ES2611403T3/es active Active
-
2014
- 2014-06-09 US US14/299,851 patent/US9551708B2/en active Active
- 2014-11-18 HK HK14111635.2A patent/HK1198125A1/xx not_active IP Right Cessation
-
2017
- 2017-01-18 US US15/409,283 patent/US20170122942A1/en not_active Abandoned
- 2017-04-21 JP JP2017084084A patent/JP6416974B2/ja not_active Expired - Fee Related
- 2017-06-23 AU AU2017204261A patent/AU2017204261B2/en not_active Ceased
-
2018
- 2018-10-25 US US16/170,870 patent/US10928393B2/en active Active
-
2021
- 2021-02-04 US US17/167,246 patent/US20210164976A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1198125A1 (en) | Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy | |
IL261768B (en) | Devices and methods for tissue treatment | |
ZA201305783B (en) | Composition and methods for treating cardiovascular diseases | |
ZA201308111B (en) | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor | |
SI2619576T1 (sl) | Sredstva in metode za predvidevanje odziva rakavega pacienta na zdravljenje | |
IL226401A0 (en) | Methods for treating disorders related to @fgfBA | |
HK1201454A1 (en) | Therapeutic agents and uses thereof | |
EP2858517A4 (en) | TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES AND THROMBOSIS | |
EP2925312A4 (en) | ENTACAPONE FOR THE PREVENTION AND TREATMENT OF ADIPOSITAS AND RELATED METABOLISM DISEASES | |
IL230433A0 (en) | Pain management methods | |
EP2694079A4 (en) | POLYMERS AND METHOD FOR PAIN TREATMENT | |
IL232135A0 (en) | Therapeutic combinations and methods for treating melanoma | |
EP2803344A4 (en) | THERAPEUTIC GYMNASTIC METHOD AND THERAPEUTIC GYMNASTIC DEVICE | |
HK1212225A1 (en) | Therapeutic formulation and methods of treatment | |
EP2575824A4 (en) | METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES | |
EP2672965A4 (en) | TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE AND THROMBOSIS | |
EP2670438A4 (en) | SELECTION AND TREATMENT OF PATIENTS | |
EP2750508A4 (en) | COMPOUNDS AND THERAPEUTIC METHODS | |
EP2710017A4 (en) | MACROCYCLIC THERAPEUTIC AGENTS AND METHODS OF TREATMENT | |
ZA201308176B (en) | Therapeutic treatment | |
GB201113140D0 (en) | Prediction and treatment of cancer | |
IL214194A0 (en) | Training and therapy apparatus | |
GB201115759D0 (en) | Therapeutic treatments | |
GB201115761D0 (en) | Therapeutic treatments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20210713 |